Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28312393 | 0.98 | ALDH1A1 (0.44) | ALDH1A1CYP2C19CYP1A2CYP2D6VCAM1 | |
| SCHEMBL10452714 | 0.85 | KMT2A (0.50) | ALDH1A1CYP2C19CYP1A2CYP2C9LMNA | |
| SCHEMBL9763798 | 0.84 | HSP90AA1 (0.42) | ALDH1A1CYP2C19CYP1A2CA2CA1 | |
| SCHEMBL6254627 | 0.82 | GRIN2D (0.41) | ALDH1A1CYP2C19CYP1A2CYP2D6CA2 | |
| SCHEMBL28829380 | 0.82 | ALDH1A1 (0.42) | ALDH1A1CYP2C19CYP1A2CYP2C9LMNA | |
| SCHEMBL30658731 | 0.81 | HSP90AA1 (0.40) | ALDH1A1CYP2C19CYP1A2CA2CA1 | |
| Hydrochloric Acid SCHEMBL11758752 | 0.81 | GRIN2D (0.40) | ALDH1A1CYP2C19CYP1A2CYP2D6CA2 | |
| SCHEMBL7531981 | 0.80 | CA2 (0.59) | ALDH1A1CYP2C19CYP1A2CYP2D6CA2 | |
| SCHEMBL31370978 | 0.80 | CA2 (0.53) | ALDH1A1CYP2C19CYP1A2CYP2D6CA2 | |
| SCHEMBL414795 | 0.80 | GPR35 (0.56) | ALDH1A1CYP2C19CYP1A2VCAM1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831648-A | The synthetic method of diazoxiide | 北京同济达药业有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-103570595-A | Preparation method of 5-chlorine-2-aminobenzene sulfonamide | SHANG ZHENHUA | 2014-02-12 | — | — | CN | claimed |
| US-3935005-A | Composition and method for stripping gold and silver | AMERICAN CHEMICAL & REFINING COMPANY, INCORPORATED (US) | 1976-01-27 | — | — | US | claimed |
| CN-106831648-B | The synthetic method of diazoxiide | 北京同济达药业有限公司 | 2019-03-12 | — | — | CN | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| EP-2598486-B1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| CN-106831648-A | The synthetic method of diazoxiide | 北京同济达药业有限公司 | 2017-06-13 | — | — | CN | disclosed |
| CN-103339111-B | Bicyclic acetyl-CoA carboxylase inhibitors | NOVARTIS AG (CH) | 2015-12-16 | — | — | CN | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| CN-103570595-A | Preparation method of 5-chlorine-2-aminobenzene sulfonamide | SHANG ZHENHUA | 2014-02-12 | — | — | CN | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| EP-0463993-B1 | Process for the preparation of aminoanthraquinone derivatives | CIBA SC HOLDING AG (CH) | 2002-05-02 | — | — | EP | disclosed |
| US-5196553-A | From bromaminic acid and a benzenesulfonamide or an amide, copper/I/ catalyst formed by in situ reduction of a copper/II/ salt, less copper required | CIBA-GEIGY CORPORATION (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0463993-A1 | Process for the preparation of aminoanthraquinone derivatives | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | disclosed |
| US-4483739-A | Compositions and method for stripping gold from copper substrates | OMI INTERNATIONAL CORPORATION (US) | 1984-11-20 | — | — | US | disclosed |
| US-3935005-A | Composition and method for stripping gold and silver | AMERICAN CHEMICAL & REFINING COMPANY, INCORPORATED (US) | 1976-01-27 | — | — | US | disclosed |
| US-3935005-A | Composition and method for stripping gold and silver | AMERICAN CHEMICAL & REFINING COMPANY, INCORPORATED (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | ALDH1A1 215/4885CYP2C19 300/4885CYP1A2 356/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | ALDH1A1 215/4885CYP2C19 300/4885CYP1A2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.